Информационное письмо о регистрации нового перорального контрацептива Джес в России
- Авторы: - -
- Выпуск: Том 10, № 6 (2008)
- Страницы: 27
- Раздел: Статьи
- URL: https://ogarev-online.ru/2079-5831/article/view/27960
- ID: 27960
Цитировать
Полный текст
Аннотация
Полный текст
Открыть статью на сайте журналаСписок литературы
- Sitruk-Ware R. New progestagens for contraceptive use. Human Reproduction Update 2006; 12 (2): 169–78.
- Mishell D.R, Jr. Rationale for decreasing the number of days of the hormone - free interval with use of low - dose oral contraceptive formulations. Contraception 2005; 71: 304–5.
- Klipping C, Duijkers I, Trummer D et al. Suppression of ovarian activity with a drospirenone - containing oral contraceptive in a 24/4 regimen. Contraception 2008.
- Gruber C, Marr J, Anttila L. A randomized study comparing the bleeding pattern of a 24-day regimen of ethinylestradiol 20mcg plus drospirenone 3mg COC with a 21-day regimen of ethinylestradiol 20mcg plus desogestrel 150mcg COC. XVIII World Congress of Gynaecology & Obstetrics (FIGO) Kuala Lumpur, Malaysia, 5–10 November 2006.
- Bachmann G, Sulak P.J, Sampson-Landers C et al. Efficacy and safety of a low - dose 24-day combined oral contraceptive containin 20 micrograms ethinylestradiol and 3 mg drospirenone. Contraception 2004; 70: 191–8.
- Yonkers K.A, Brown C, Pearlstein T.B et al. Efficacy of a new low - dose oral contraceptive with drospirenone in premenstrual dysphoric disorder. Obstet Gynecol 2005; 106 (3): 492–501.
- Koltun W, Lucky A, Sampson - Landers C et al. A randomized controlled trial of a low - dose COC containing ethinylestradiol 20 mcg + drospirenone 3mg in the treatment of acne vulgaris: i) reduction in acne lesions, and investigator global assessment. XVIII World Congress of Gynaecology & Obstetrics (FIGO) Kuala Lumpur, Malaysia, 5–10 November 2006.
Дополнительные файлы
